Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Safety and Tolerability of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients

NCT06057454 is registered in ClinicalTrials.gov with Rise Therapeutics LLC as lead sponsor.

NCT NCT06057454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06057454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Safety and Tolerability of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
Lead sponsor
Rise Therapeutics LLC
Phase
Phase 1
Overall status
Completed
Start date
December 5, 2023
Completion date
November 5, 2025
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1, type 1 diabetes, type 1 diabetes (juvenile onset)